Compare UiPath Inc (PATH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Sanofi SA — how do they compare? UiPath Inc trades at $13.61 (market cap $7.26B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 14.3× UiPath Inc's market cap, and Sanofi SA pays a 5.61% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| PATH | SNY | |
|---|---|---|
Market Cap | $7.26B | $104.06B |
Sector | Technology | Health |
52-Week High | $19.29 | $52.34 |
52-Week Low | $9.38 | $41.33 |
Enterprise Value | $6.05B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $14.01, down 7.77% amid mixed signals. The stock is near its consensus price target low of $14.00. Revenue growth is improving, with 2025 revenue at $1.43 billion and a projected net profit margin of 21.03% for 2026. Technical indicators show a bearish near-term trend with RSI at oversold levels, while recent news highlights volatility following Q2 earnings.
The outlook is cautious; PATH shows fundamental improvement but faces execution risks and competitive pressure. Analyst consensus is predominantly Hold (70.84%), with a $17.38 price target suggesting modest upside. Key risks include slowing growth guidance and macroeconomic headwinds impacting software demand.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
